MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Closed

SectorHealthcare

6.74 5.97

Buy Sell

Overview

Share price change

24h

Current

Min

6.36

Max

6.82

Key metrics
By Trading Economics
Income	3M 12M
Sales	21M 76M
P/E Sector Avg	10.049 56.063
Profit margin	15.633
Employees	179
EBITDA	13M 27M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-21.75% downside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-46M 312M
Previous open	0.77
Previous close	6.74

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 kwi 2026, 22:56 UTC

Major News Events

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 kwi 2026, 20:50 UTC

Acquisitions, Mergers, Takeovers

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 kwi 2026, 23:55 UTC

Market Talk

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 kwi 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 kwi 2026, 23:23 UTC

Major News Events

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 kwi 2026, 23:07 UTC

Earnings

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 kwi 2026, 23:02 UTC

Major News Events

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 kwi 2026, 22:39 UTC

Earnings

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 kwi 2026, 22:08 UTC

Market Talk

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 kwi 2026, 22:00 UTC

Major News Events

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 kwi 2026, 22:00 UTC

Major News Events

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 kwi 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 kwi 2026, 21:31 UTC

Major News Events

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 kwi 2026, 20:38 UTC

Earnings

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 kwi 2026, 20:31 UTC

Acquisitions, Mergers, Takeovers

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 kwi 2026, 20:16 UTC

Acquisitions, Mergers, Takeovers

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 kwi 2026, 20:16 UTC

Acquisitions, Mergers, Takeovers

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 kwi 2026, 20:13 UTC

Acquisitions, Mergers, Takeovers

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 kwi 2026, 20:07 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 kwi 2026, 20:07 UTC

Acquisitions, Mergers, Takeovers

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-21.75% downside

12 Months Forecast

Average 5 USD -21.75%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Recent bullish events outweigh bearish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.